Getting Your GLP-1 Covered by Insurance: A Step-by-Step Guide

The first call about GLP-1 coverage tends to go badly. A patient calls their insurer, asks whether Wegovy or Zepbound is covered, and gets an answer that sounds definitive — yes, no, or "not for that indication" — that turns out to be only partly accurate. The actual coverage decision involves several layers: formulary placement, prior authorization criteria, step therapy requirements, and benefit design choices that the front-line representative often cannot see in full.

Getting coverage approved is rarely a single transaction. It is a procedural sequence with predictable failure points, and patients who understand the sequence in advance tend to navigate it considerably faster than patients who learn each step at the moment they encounter it.

Step one: confirm formulary status before anything else

The formulary is the insurer's list of covered drugs and the tier each drug sits on. Before any prescription is written, the patient or the prescriber's office should confirm which GLP-1 medications appear on the formulary and at what tier. The patient's member portal usually has this information under "find a drug" or "drug list." If the portal is unclear, calling the pharmacy benefit manager (PBM) — not the medical plan — and asking specifically about Wegovy, Zepbound, Ozempic, and Mounjaro by name will produce the cleanest answer.

The terminology matters. "Covered" on the formulary does not mean "covered without restrictions." Most GLP-1 medications sit on specialty or non-preferred tiers with prior authorization requirements. Confirming formulary status simply establishes whether coverage is procedurally possible at all. Plans that exclude all GLP-1 medications for obesity (some self-funded employer plans do) will not approve a prior authorization no matter how strong the documentation is.

Step two: match the indication to the drug

The four major GLP-1 medications have distinct FDA-approved indications, and insurance coverage tracks those indications closely.

Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in patients with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, and — since 2024 — for cardiovascular risk reduction in patients with established cardiovascular disease and overweight or obesity. Zepbound (tirzepatide) carries the same chronic weight management indication and an additional indication for moderate-to-severe obstructive sleep apnea in adults with obesity.

Ozempic (semaglutide) and Mounjaro (tirzepatide) are approved for type 2 diabetes, not for weight loss. Insurance approval for these products for weight loss alone is rare and generally requires the prescriber to document a diabetes indication. Off-label weight-loss prescribing of Ozempic or Mounjaro typically results in coverage denial.

Matching the drug to the appropriate indication is foundational. A prior authorization request for Wegovy with documented obesity is a different conversation than a prior authorization request for Ozempic for weight loss — and the latter is rarely going anywhere.

BMI thresholds and comorbidity documentation

Most plans follow the FDA label thresholds: BMI ≥30 with no comorbidity required, or BMI ≥27 with at least one weight-related condition. The comorbidities that typically qualify include type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, non-alcoholic fatty liver disease, and osteoarthritis.

The clinical chart needs to document both the BMI and the comorbidity clearly, with diagnosis codes (ICD-10) and ideally with recent measurements. A patient whose BMI is 27.4 with hypertension diagnosed two years earlier but not consistently documented in recent visits may face a denial on documentation grounds. The fix is usually straightforward — the prescriber updates the chart and resubmits — but it adds days to the process.

Step three: navigate step therapy

Step therapy is the insurer's requirement that a patient try lower-cost or preferred alternatives before approval of a non-preferred drug. For GLP-1 medications, step therapy criteria vary widely but commonly include:

Documented previous attempts at weight loss through diet and exercise, usually defined as at least three to six months of structured effort. This documentation can come from the patient's own records, prior provider notes, or attestation from the prescriber based on patient history. Some plans require participation in a specific weight-management programme.

For some plans, a trial of phentermine, orlistat, or naltrexone-bupropion before approval of a GLP-1. This requirement is less common in 2026 than it was in 2022 — the clinical case for older agents as a step therapy precondition has weakened — but it persists on some formularies, particularly for self-funded employer plans.

For plans that cover multiple GLP-1s, a preferred-product requirement. Many formularies designate one product as preferred (often Wegovy over Zepbound, or vice versa depending on the rebate contract) and require documentation of why the non-preferred product is clinically necessary before approving it.

Step therapy is the most common reason for denial of an otherwise reasonable prior authorization request. The fix is usually documentation rather than appeal — providing the missing trial history or accepting the preferred product if clinically acceptable.

Step four: submit the prior authorization

The prior authorization (PA) is the formal request from the prescriber to the insurer for approval to dispense the medication. It is submitted by the prescribing office, not the patient, typically through an electronic platform like CoverMyMeds, Surescripts, or the insurer's own portal.

A complete PA submission typically includes:

Patient demographics, current BMI with date of measurement, weight history showing chronicity, qualifying comorbidities with ICD-10 codes, documented prior weight-loss attempts and outcomes, prior pharmacotherapy trials and reasons for failure or intolerance, the prescriber's clinical rationale for the requested medication, and contraindications to alternative therapies if relevant.

Most insurers respond to PA requests within 72 hours for non-urgent submissions. Many respond within 24 hours when the documentation is complete. Incomplete submissions trigger requests for additional information, which extend the timeline by days or weeks.

The patient's role at this stage is to provide accurate weight history and prior-attempt information to the prescribing office and to confirm that the submission has been made. Tracking the PA number and the submission date matters for follow-up. Detailed strategies for getting through PA on the first attempt are covered in our companion guide to prior authorization tips.

Step five: handle the denial (because there's often a denial)

A 2023 analysis by the Institute for Clinical and Economic Review (ICER) examined GLP-1 coverage patterns and found high rates of initial denial across commercial plans, often based on documentation deficiencies rather than substantive ineligibility. Several published audits of obesity medication prior authorization have found first-pass approval rates well below 50%.

If the PA is denied, the insurer must issue a denial letter explaining the specific reason. The denial reason determines the appropriate next step.

Documentation-based denials (missing BMI, insufficient comorbidity documentation, missing prior-attempt history) are typically resolved by the prescriber submitting additional information. This is technically an appeal but procedurally a resubmission with the missing data.

Step-therapy denials require either documenting the trial of the required alternative or appealing on clinical grounds (the alternative is contraindicated, has been tried unsuccessfully, or is inappropriate for a documented reason). Endocrinologists and obesity medicine specialists are generally more practiced at writing the clinical-grounds appeals than primary care offices, though primary care can do it effectively with a template.

Coverage-exclusion denials (the plan does not cover GLP-1s for obesity at all) cannot usually be appealed clinically. The only paths are an HR-mediated benefits change for employer-sponsored plans, switching plans during open enrolment, or pursuing alternative pricing through cash and manufacturer programmes.

The internal vs external appeal sequence

For denials based on medical necessity, federal law (ACA section 2719) guarantees two appeal levels for most commercial plans: an internal appeal handled by the insurer, and an external appeal handled by an independent review organisation (IRO). The IRO is binding on the insurer. External appeals of GLP-1 denials have a higher overturn rate than internal appeals, partly because IROs apply clinical evidence standards rather than plan-specific cost criteria.

The external appeal process generally takes 30–60 days. For patients with cardiovascular indications, obstructive sleep apnea documented by sleep study, or other strong clinical justifications beyond BMI alone, the external appeal route is worth pursuing if internal appeals fail.

Step six: manage the approval window

Approved prior authorizations typically have a defined duration — often one year, sometimes shorter. Some plans require documented weight loss (often 5% at six months) to continue authorization beyond the initial period. Reauthorization is generally a lighter procedural lift than initial authorization, but the prescribing office still needs to submit updated documentation before the original PA expires.

Calendar reminders for reauthorization timing prevent gaps in medication coverage that can otherwise interrupt treatment and produce the regain biology documented in maintenance-phase research.

The plan types worth understanding

Coverage outcomes vary substantially by plan type. Self-funded employer plans (where the employer pays claims directly and contracts with an insurer for administration) have wide latitude to include or exclude obesity medications. Fully-insured employer plans follow the insurer's standard formulary more closely. Marketplace plans under the ACA follow state-by-state benchmark plan rules. State Medicaid programmes vary considerably — some cover GLP-1s for obesity with prior authorization, others exclude them entirely. Medicare, as covered in the cost guide, excludes weight-loss indications but covers cardiovascular indications under specific conditions.

For patients facing structural coverage exclusion, the procedural workflow above will not change the outcome. The fork in the road is whether the plan covers GLP-1s for obesity at all, and that question is best answered up front rather than after multiple PA submissions.

Key takeaways

• Confirm formulary status and any prior authorization or step therapy requirements before writing the prescription — the patient portal or PBM call is the cleanest source.
• Match the drug to the indication: Wegovy and Zepbound for obesity and related conditions, Ozempic and Mounjaro for diabetes; off-label weight-loss prescribing of diabetes products is rarely covered.
• BMI ≥30, or ≥27 with a documented weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, CVD, NAFLD, osteoarthritis), is the standard label threshold most plans follow.
• Step therapy is the most common denial reason; documenting prior weight-loss attempts, prior pharmacotherapy trials, or clinical contraindications to alternatives addresses most cases.
• Most initial PA denials are documentation-based, not substantive; appeal rates and external review overturn rates are high when clinical justification is strong.
• Plan type matters: self-funded employer plans, fully-insured plans, marketplace plans, Medicaid, and Medicare each have different baseline coverage structures that determine what the procedural workflow can achieve.